Historique
Périodique
The use of plasma levels to optimize methadone maintenance treatment
(Test plasmatiques en vue d'optimiser le traitement de maintenance à la méthadone)
Auteur(s) :
LOIMER, N. ;
SCHMID, R.
Année
1992
Langue(s) :
Anglais
ISBN :
0376-8716
Refs biblio. :
21
Domaine :
Drogues illicites / Illicit drugs
Note générale :
Drug and Alcohol Dependence, 1992, 30, 241-246
Résumé :
FRANÇAIS :
Cette étude veut montrer qu'un monitoring régulier du taux de méthadone plasmatique, chez des toxicomanes en traitement de maintenance, permet d'adapter les doses de méthadone distribuées, d'éviter les rechutes et donc les comportements à risque ; ceci s'inscrit dans une optique de prévention du sida.
ENGLISH :
The question of the optimal methadone dose during maintenance therapy is controversial. This study examines, in 104 methadone patients, the relation between self-rating, observer-rating, urine tests, HIV-1 serostatus, daily methadone doses and plasma levels of methadone. No differences were found between HIV-1 infected and seronegative patients in these respects. The optimal methadone plasma level as judged by selfand observer-rating was more than 150 ng/ml. For oral methadone, the best results are obtained in patients receiving more than 90 mg daily. We found a significant relationship between methadone dose and plasma levels, also in patients who also used illicit drugs. We conclude that therapeutic drug monitoring should become routine in methadone treatment to achieve optimum results, especially in patients who complain of withdrawal symptoms and continue high-risk behaviour. (Author's abstract)
Cette étude veut montrer qu'un monitoring régulier du taux de méthadone plasmatique, chez des toxicomanes en traitement de maintenance, permet d'adapter les doses de méthadone distribuées, d'éviter les rechutes et donc les comportements à risque ; ceci s'inscrit dans une optique de prévention du sida.
ENGLISH :
The question of the optimal methadone dose during maintenance therapy is controversial. This study examines, in 104 methadone patients, the relation between self-rating, observer-rating, urine tests, HIV-1 serostatus, daily methadone doses and plasma levels of methadone. No differences were found between HIV-1 infected and seronegative patients in these respects. The optimal methadone plasma level as judged by selfand observer-rating was more than 150 ng/ml. For oral methadone, the best results are obtained in patients receiving more than 90 mg daily. We found a significant relationship between methadone dose and plasma levels, also in patients who also used illicit drugs. We conclude that therapeutic drug monitoring should become routine in methadone treatment to achieve optimum results, especially in patients who complain of withdrawal symptoms and continue high-risk behaviour. (Author's abstract)
Affiliation :
Psychiatr. Univ. Klin., Waehringer Gürtel, A-1090 Vienna
Autriche. Austria.
Autriche. Austria.